Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Board declares interim dividend of Rs 2 per equity share
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
All India Institute of Ayurveda hosts ministers and showcase their achievements
The company expects revenue growth of 10-15 per cent in the US
The transaction is expected to close in the Q4FY22
Advances deployment of mRNA technology across vaccines and therapeutics development
This robust growth has come despite the raging pandemic for most part of the quarter
Subscribe To Our Newsletter & Stay Updated
